Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2026)

Sunshine Biopharma filings provide 4 years of Restructuring Costs readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Restructuring Costs rose 67.48% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 26.26% increase, with the full-year FY2025 number at $3.9 million, up 24.26% from a year prior.
  • Restructuring Costs hit $1.5 million in Q4 2025 for Sunshine Biopharma, up from $614661.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.5 million in Q4 2025 to a low of $530334.0 in Q3 2024.
  • Median Restructuring Costs over the past 3 years was $763451.0 (2023), compared with a mean of $818994.2.
  • Biggest five-year swings in Restructuring Costs: dropped 2.55% in 2024 and later soared 67.48% in 2025.
  • Sunshine Biopharma's Restructuring Costs stood at $720297.0 in 2023, then rose by 25.79% to $906056.0 in 2024, then soared by 67.48% to $1.5 million in 2025.
  • The last three reported values for Restructuring Costs were $1.5 million (Q4 2025), $614661.0 (Q3 2025), and $806605.0 (Q2 2025) per Business Quant data.